Age-related Macular Degeneration Drugs and Forecast Market
1 Introduction to Research & Analysis Reports
1.1 Age-relatedMacularDegeneration (ARMD) Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Age-relatedMacularDegeneration (ARMD) Drugs Overall Market Size
2.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size: 2022 VS 2032
2.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size, Prospects & Forecasts: 2018-2032
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Age-relatedMacularDegeneration (ARMD) Drugs Players in Global Market
3.2 Top Global Age-relatedMacularDegeneration (ARMD) Drugs Companies Ranked by Revenue
3.3 Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Companies
3.4 Top 3 and Top 5 Age-relatedMacularDegeneration (ARMD) Drugs Companies in Global Market, by Revenue in 2022
3.5 Global Companies Age-relatedMacularDegeneration (ARMD) Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Age-relatedMacularDegeneration (ARMD) Drugs Players in Global Market
3.6.1 List of Global Tier 1 Age-relatedMacularDegeneration (ARMD) Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Age-relatedMacularDegeneration (ARMD) Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Markets, 2022 & 2032
4.1.2 Anti VEGF Drugs
4.1.3 Photosensitive Drugs
4.1.4 Others
4.2 By Type - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue & Forecasts
4.2.1 By Type - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2018-2023
4.2.2 By Type - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2024-2032
4.2.3 By Type - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2018-2032
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2022 & 2032
5.1.2 Exudative ARMD
5.1.3 Atrophy ARMD
5.2 By Application - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue & Forecasts
5.2.1 By Application - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2018-2023
5.2.2 By Application - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2024-2032
5.2.3 By Application - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2018-2032
6 Sights by Region
6.1 By Region - Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2022 & 2032
6.2 By Region - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue & Forecasts
6.2.1 By Region - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2018-2023
6.2.2 By Region - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2024-2032
6.2.3 By Region - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2018-2032
6.3 North America
6.3.1 By Country - North America Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2018-2032
6.3.2 US Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.3.3 Canada Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.3.4 Mexico Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.4 Europe
6.4.1 By Country - Europe Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2018-2032
6.4.2 Germany Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.4.3 France Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.4.4 U.K. Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.4.5 Italy Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.4.6 Russia Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.4.7 Nordic Countries Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.4.8 Benelux Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.5 Asia
6.5.1 By Region - Asia Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2018-2032
6.5.2 China Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.5.3 Japan Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.5.4 South Korea Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.5.5 Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.5.6 India Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.6 South America
6.6.1 By Country - South America Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2018-2032
6.6.2 Brazil Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.6.3 Argentina Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2018-2032
6.7.2 Turkey Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.7.3 Israel Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.7.4 Saudi Arabia Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.7.5 UAE Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
7 Age-relatedMacularDegeneration (ARMD) Drugs Companies Profiles
7.1 Roche
7.1.1 Roche Company Summary
7.1.2 Roche Business Overview
7.1.3 Roche Age-relatedMacularDegeneration (ARMD) Drugs Major Product Offerings
7.1.4 Roche Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global Market (2018-2023)
7.1.5 Roche Key News & Latest Developments
7.2 Regeneron Pharmaceuticals
7.2.1 Regeneron Pharmaceuticals Company Summary
7.2.2 Regeneron Pharmaceuticals Business Overview
7.2.3 Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Major Product Offerings
7.2.4 Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global Market (2018-2023)
7.2.5 Regeneron Pharmaceuticals Key News & Latest Developments
7.3 Bayer
7.3.1 Bayer Company Summary
7.3.2 Bayer Business Overview
7.3.3 Bayer Age-relatedMacularDegeneration (ARMD) Drugs Major Product Offerings
7.3.4 Bayer Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global Market (2018-2023)
7.3.5 Bayer Key News & Latest Developments
7.4 Santen Oy
7.4.1 Santen Oy Company Summary
7.4.2 Santen Oy Business Overview
7.4.3 Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Major Product Offerings
7.4.4 Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global Market (2018-2023)
7.4.5 Santen Oy Key News & Latest Developments
7.5 Kanghong Pharmaceuticals
7.5.1 Kanghong Pharmaceuticals Company Summary
7.5.2 Kanghong Pharmaceuticals Business Overview
7.5.3 Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Major Product Offerings
7.5.4 Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global Market (2018-2023)
7.5.5 Kanghong Pharmaceuticals Key News & Latest Developments
7.6 Novartis
7.6.1 Novartis Company Summary
7.6.2 Novartis Business Overview
7.6.3 Novartis Age-relatedMacularDegeneration (ARMD) Drugs Major Product Offerings
7.6.4 Novartis Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global Market (2018-2023)
7.6.5 Novartis Key News & Latest Developments
7.7 Eli Lilly and Company
7.7.1 Eli Lilly and Company Company Summary
7.7.2 Eli Lilly and Company Business Overview
7.7.3 Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Major Product Offerings
7.7.4 Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global Market (2018-2023)
7.7.5 Eli Lilly and Company Key News & Latest Developments
7.8 TRACON Pharmaceuticals
7.8.1 TRACON Pharmaceuticals Company Summary
7.8.2 TRACON Pharmaceuticals Business Overview
7.8.3 TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Major Product Offerings
7.8.4 TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global Market (2018-2023)
7.8.5 TRACON Pharmaceuticals Key News & Latest Developments
7.9 Pfizer
7.9.1 Pfizer Company Summary
7.9.2 Pfizer Business Overview
7.9.3 Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Major Product Offerings
7.9.4 Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global Market (2018-2023)
7.9.5 Pfizer Key News & Latest Developments
7.10 GSK
7.10.1 GSK Company Summary
7.10.2 GSK Business Overview
7.10.3 GSK Age-relatedMacularDegeneration (ARMD) Drugs Major Product Offerings
7.10.4 GSK Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global Market (2018-2023)
7.10.5 GSK Key News & Latest Developments
7.11 BIOCAD
7.11.1 BIOCAD Company Summary
7.11.2 BIOCAD Business Overview
7.11.3 BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Major Product Offerings
7.11.4 BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global Market (2018-2023)
7.11.5 BIOCAD Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
List of Tables
Table 1. Age-relatedMacularDegeneration (ARMD) Drugs Market Opportunities & Trends in Global Market
Table 2. Age-relatedMacularDegeneration (ARMD) Drugs Market Drivers in Global Market
Table 3. Age-relatedMacularDegeneration (ARMD) Drugs Market Restraints in Global Market
Table 4. Key Players of Age-relatedMacularDegeneration (ARMD) Drugs in Global Market
Table 5. Top Age-relatedMacularDegeneration (ARMD) Drugs Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Share by Companies, 2018-2023
Table 8. Global Companies Age-relatedMacularDegeneration (ARMD) Drugs Product Type
Table 9. List of Global Tier 1 Age-relatedMacularDegeneration (ARMD) Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Age-relatedMacularDegeneration (ARMD) Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2022 & 2032
Table 12. By Type - Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global (US$, Mn), 2024-2032
Table 14. By Application ? Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2022 & 2032
Table 15. By Application - Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global (US$, Mn), 2024-2032
Table 17. By Region ? Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2022 & 2032
Table 18. By Region - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$, Mn), 2024-2032
Table 20. By Country - North America Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2024-2032
Table 22. By Country - Europe Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2024-2032
Table 24. By Region - Asia Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2024-2032
Table 26. By Country - South America Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2024-2032
Table 28. By Country - Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2024-2032
Table 30. Roche Company Summary
Table 31. Roche Age-relatedMacularDegeneration (ARMD) Drugs Product Offerings
Table 32. Roche Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$, Mn) & (2018-2023)
Table 33. Roche Key News & Latest Developments
Table 34. Regeneron Pharmaceuticals Company Summary
Table 35. Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product Offerings
Table 36. Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$, Mn) & (2018-2023)
Table 37. Regeneron Pharmaceuticals Key News & Latest Developments
Table 38. Bayer Company Summary
Table 39. Bayer Age-relatedMacularDegeneration (ARMD) Drugs Product Offerings
Table 40. Bayer Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$, Mn) & (2018-2023)
Table 41. Bayer Key News & Latest Developments
Table 42. Santen Oy Company Summary
Table 43. Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Product Offerings
Table 44. Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$, Mn) & (2018-2023)
Table 45. Santen Oy Key News & Latest Developments
Table 46. Kanghong Pharmaceuticals Company Summary
Table 47. Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product Offerings
Table 48. Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$, Mn) & (2018-2023)
Table 49. Kanghong Pharmaceuticals Key News & Latest Developments
Table 50. Novartis Company Summary
Table 51. Novartis Age-relatedMacularDegeneration (ARMD) Drugs Product Offerings
Table 52. Novartis Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$, Mn) & (2018-2023)
Table 53. Novartis Key News & Latest Developments
Table 54. Eli Lilly and Company Company Summary
Table 55. Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Product Offerings
Table 56. Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$, Mn) & (2018-2023)
Table 57. Eli Lilly and Company Key News & Latest Developments
Table 58. TRACON Pharmaceuticals Company Summary
Table 59. TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product Offerings
Table 60. TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$, Mn) & (2018-2023)
Table 61. TRACON Pharmaceuticals Key News & Latest Developments
Table 62. Pfizer Company Summary
Table 63. Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Product Offerings
Table 64. Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$, Mn) & (2018-2023)
Table 65. Pfizer Key News & Latest Developments
Table 66. GSK Company Summary
Table 67. GSK Age-relatedMacularDegeneration (ARMD) Drugs Product Offerings
Table 68. GSK Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$, Mn) & (2018-2023)
Table 69. GSK Key News & Latest Developments
Table 70. BIOCAD Company Summary
Table 71. BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Product Offerings
Table 72. BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$, Mn) & (2018-2023)
Table 73. BIOCAD Key News & Latest Developments
List of Figures
Figure 1. Age-relatedMacularDegeneration (ARMD) Drugs Segment by Type in 2022
Figure 2. Age-relatedMacularDegeneration (ARMD) Drugs Segment by Application in 2022
Figure 3. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size: 2022 VS 2032 (US$, Mn)
Figure 6. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2018-2032 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Age-relatedMacularDegeneration (ARMD) Drugs Revenue in 2022
Figure 8. By Type - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2018-2032
Figure 9. By Application - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2018-2032
Figure 10. By Type - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2022 & 2032
Figure 11. By Type - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2018-2032
Figure 12. By Application - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2022 & 2032
Figure 13. By Application - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2018-2032
Figure 14. By Region - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2018-2032
Figure 15. By Country - North America Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2018-2032
Figure 16. US Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 17. Canada Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 18. Mexico Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 19. By Country - Europe Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2018-2032
Figure 20. Germany Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 21. France Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 22. U.K. Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 23. Italy Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 24. Russia Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 25. Nordic Countries Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 26. Benelux Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 27. By Region - Asia Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2018-2032
Figure 28. China Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 29. Japan Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 30. South Korea Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 31. Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 32. India Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 33. By Country - South America Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2018-2032
Figure 34. Brazil Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 35. Argentina Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 36. By Country - Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2018-2032
Figure 37. Turkey Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 38. Israel Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 39. Saudi Arabia Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 40. UAE Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 41. Roche Age-relatedMacularDegeneration (ARMD) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Bayer Age-relatedMacularDegeneration (ARMD) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Novartis Age-relatedMacularDegeneration (ARMD) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. GSK Age-relatedMacularDegeneration (ARMD) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Industry Market Size
